Evidence map›Paper›PMID 34711878›Full record

ArticleScientific reports2021

Mapping of population disparities in the cholangiocarcinoma urinary metabolome.

Munirah Alsaleh, Zoe Leftley, Thomas O'Connor, Thomas Hughes, Thomas A Barbera, Larry K Koomson, Abigail Zabron, Helen Reeves, Matthew Cramp, Stephen D Ryder and 13 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. PeerJ · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 8 institutions in 2 countries.

Munirah AlsalehDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, W2 INY, UK.
Zoe LeftleyDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, W2 INY, UK.
Thomas O'ConnorDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, W2 INY, UK.
Thomas HughesDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, W2 INY, UK.
Thomas A BarberaDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, W2 INY, UK.
Larry K KoomsonDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, W2 INY, UK.
Abigail ZabronDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, W2 INY, UK.
Helen ReevesNorthern Institute for Cancer Research, Paul O'Gorman Building, Medical School, University of Newcastle, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.
Matthew CrampLiver Unit, Derriford Hospital, Derriford Road, Crownhill, Plymouth, PL6 8DH, Devon, UK.
Stephen D RyderNIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and Nottingham Digestive Diseases Centre, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK.
Shaun GreerCentre for Hepatology, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL, UK.
Martin PrinceCentre for Hepatology, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL, UK.
Paiboon SithithawornCholangiocarcinoma Research Centre, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.
Narong KhuntikeoCholangiocarcinoma Research Centre, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.
Watcharin LoilomeCholangiocarcinoma Research Centre, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.
Puangrat YongvanitCholangiocarcinoma Research Centre, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.
I Jane CoxFoundation for Liver Research, The Roger Williams Institute of Hepatology, 111 Coldharbour Lane, London, SE5 9NT, UK.
Roger WilliamsFoundation for Liver Research, The Roger Williams Institute of Hepatology, 111 Coldharbour Lane, London, SE5 9NT, UK.
Christopher A WadsworthDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, W2 INY, UK.
Elaine HolmesDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, W2 INY, UK.
Kathryn NashLiver Unit, Southampton General Hospital, Tremona Rd, Southampton, SO16 6YD, Hampshire, UK.
Ross AndrewsDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, W2 INY, UK.
Simon D Taylor-RobinsonDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, W2 INY, UK. s.taylor-robinson@imperial.ac.uk.
Imperial College London · GBKhon Kaen University · THManchester Royal Infirmary · GBWilliams (United Kingdom) · GBDerriford Hospital · GBNewcastle University · GBSouthampton General Hospital · GBUniversity of Nottingham · GB

Funding

Cancer Research UK 26813Wellcome Trust
6 · The paper itself

Abstract

Phenotypic diversity in urinary metabolomes of different geographical populations has been recognized recently. In this study, urinary metabolic signatures from Western (United Kingdom) and South-East Asian (Thai) cholangiocarcinoma patients were characterized to understand spectral variability due to host carcinogenic processes and/or exogenous differences (nutritional, environmental and pharmaceutical). Urinary liquid chromatography mass spectroscopy (LC-MS) spectral profiles from Thai (healthy = 20 and cholangiocarcinoma = 14) and UK cohorts (healthy = 22 and cholangiocarcinoma = 10) were obtained and modelled using chemometric data analysis. Healthy metabolome disparities between the two distinct populations were primarily related to differences in dietary practices and body composition. Metabolites excreted due to drug treatment were dominant in urine specimens from cholangiocarcinoma patients, particularly in Western individuals. Urine from participants with sporadic (UK) cholangiocarcinoma contained greater levels of a nucleotide metabolite (uridine/pseudouridine). Higher relative concentrations of 7-methylguanine were observed in urine specimens from Thai cholangiocarcinoma patients. The urinary excretion of hippurate and methyladenine (gut microbial-host co-metabolites) showed a similar pattern of lower levels in patients with malignant biliary tumours from both countries. Intrinsic (body weight and body composition) and extrinsic (xenobiotic metabolism) factors were the main causes of disparities between the two populations. Regardless of the underlying aetiology, biological perturbations associated with cholangiocarcinoma urine metabolome signatures appeared to be influenced by gut microbial community metabolism. Dysregulation in nucleotide metabolism was associated with sporadic cholangiocarcinoma, possibly indicating differences in mitochondrial energy production pathways between cholangiocarcinoma tumour subtypes. Mapping population-specific metabolic disparities may aid in interpretation of disease processes and identification of candidate biomarkers.

Indexed as

Biological Variation, PopulationMetabolomeMetabolomicsAdultAgedAged, 80 and overBiomarkersCholangiocarcinomaChromatography, LiquidFemaleHumansMaleMass SpectrometryMiddle AgedPopulation SurveillanceThailandBiomarkers

Identifiers

PMID34711878
PMCPMC8553759
OpenAlexW3180685124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.